Company News

Getz Healthcare Taiwan recently participated in Post JET 2025, a follow-up symposium to the annual JET conference, hosted by our partner Boston Scientific. This event brings together physicians to exchange insights, discuss emerging techniques, and explore new data in interventional cardiology.

One of the key highlights this year was the growing interest in hybrid treatment approaches, particularly Drug Within Drug (DWD), compared to the traditional Full Metal Jacket method. While DWD has been discussed in previous years, it gained significant traction at this year’s forum, especially in relation to reducing hospital readmissions. The debate revealed that clinical outcomes between the two approaches may be more aligned than previously thought—offering new perspectives for promoting procedural options to physicians.

Post JET continues to be a valuable platform for open dialogue, where even untested ideas or resurfacing trends can spark innovation. These conversations help us better understand the evolving needs of healthcare professionals and guide us in delivering meaningful solutions.